For example, Rong et al. conducted a phase I pilot trial on the MUC1-peptide DC vaccine in metastatic PC patients and found the vaccine enhanced the immunological response to the tumor antigen MUC1 in metastatic PC patients without significant toxicity [16]. This evidence concerns the gene MUC1 and pachyonychia congenita.